U.S., Nov. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07226154) titled 'Prediction of Neoadjuvant Chemotherapy Response in Pancreatic Cancer' on Nov. 03.
Brief Summary: This study aims to develop and validate a predictive microRNA (miRNA) panel to assess the response to neoadjuvant chemotherapy (NACT) in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma (PDAC).
Study Start Date: Nov. 15, 2024
Study Type: OBSERVATIONAL
Condition:
Pancreatic Ductal Adenocarcinoma
Intervention:
DIAGNOSTIC_TEST: Small RNA sequencing
High-throughput small RNA sequencing performed on pre-treatment plasma samples from PDAC patients in the Discovery cohort to identify candidate microRNAs...